Early-life glucocorticoid exposure: The hypothalamic-pituitary-adrenal axis, placental function, and longterm disease risk

Endocrine Reviews

Volumn 34, Issue 6, 2013, Pages 885-916

  Braun, Thorsten ^a   Challis, John R ^b,c,d   Newnham, John P ^b   Sloboda, Deborah M ^e  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c UNIVERSITY OF TORONTO   (Canada)

^d SIMON FRASER UNIVERSITY   (Canada)

^e MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; BETAMETHASONE; CARRIER PROTEIN; CORTICOSTEROID; CORTICOTROPIN; DEXAMETHASONE; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; HUMAN PLACENTA LACTOGEN; HYDROCORTISONE; NEUROPEPTIDE;

ADAPTATION; AMINO ACID TRANSPORT; BEHAVIOR DISORDER; CARDIOVASCULAR FUNCTION; CHILD BEHAVIOR; COGNITION; DISEASE PREDISPOSITION; DRUG EFFECT; DRUG SAFETY; FETUS DEVELOPMENT; FETUS GROWTH; GENETIC REGULATION; GLUCOSE TRANSPORT; HORMONE ACTION; HUMAN; HYPERTENSION; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INSULIN RESISTANCE; METABOLIC DISORDER; METABOLISM; NONHUMAN; PLACENTA FUNCTION; PREMATURE LABOR; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; REPRODUCTION; REVIEW; SIGNAL TRANSDUCTION; SYSTEMATIC REVIEW;

ANIMALS; DISEASE; FEMALE; FETAL DEVELOPMENT; GLUCOCORTICOIDS; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; INFANT, NEWBORN; PITUITARY-ADRENAL SYSTEM; PLACENTA; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; RISK FACTORS;

EID: 84890843410     PISSN: 0163769X     EISSN: None     Source Type: Journal    
DOI: 10.1210/er.2013-1012     Document Type: Review

References (419)

1. Plagemann A. Maternal diabetes and perinatal programming. Early Hum Dev. 2011;87:743-747.
2. Plagemann A. Perinatal programming and functional teratogenesis: impact on body weight regulation and obesity. Physiol Behav. 2005;86:661-668.
3. Newnham JP, Pennell CE, Lye SJ, Rampono J, Challis JR. Early life origins of obesity. Obstet Gynecol Clin North Am. 2009;36:227-244, xii
4. Jones RH, Ozanne SE. Fetal programming of glucose-insulin metabolism. Mol Cell Endocrinol. 2009;297:4-9.
5. Harris A, Seckl J. Glucocorticoids, prenatal stress and the programming of disease. Horm Behav. 2011;59:279-289.
6. Plagemann A. Perinatal nutrition and hormone-dependent programming of food intake. Horm Res. 2006;65(Suppl 3):83- 89.
7. Barouki R, Gluckman PD, Grandjean P, Hanson M, Heindel JJ. Developmental origins of non-communicable disease: implications for research and public health. Environ Health. 2012;11:42.
8. Hanson M, Gluckman P. Developmental origins of noncommunicable disease: population and public health implications. Am J Clin Nutr. 2011;94:1754S-1758S.
9. Godfrey KM, Gluckman PD, Hanson MA. Developmental origins of metabolic disease: life course and intergenerational perspectives. Trends Endocrinol Metab. 2010;21: 199-205.
10. Newnham JP. Is prenatal glucocorticoid administration another origin of adult disease? Clin Exp Pharmacol Physiol. 2001;28:957-961.
11. Newnham JP, Moss TJ, Nitsos I, Sloboda DM, Challis JR. Nutrition and the early origins of adult disease. Asia Pac J Clin Nutr. 2002;11(Suppl 3):S537-S542.
12. Challis J, Sloboda D, Matthews S, et al. Fetal hypothalamic-pituitary adrenal (HPA) development and activation as a determinant of the timing of birth, and of postnatal disease. Endocr Res. 2000;26:489-504.
13. Clifton VL. Sexually dimorphic effects of maternal asthma during pregnancy on placental glucocorticoid metabolism and fetal growth. Cell Tissue Res. 2005;322:63-71.
14. Clifton VL, Rennie N, Murphy VE. Effect of inhaled glucocorticoid treatment on placental 11β-hydroxysteroid dehydrogenase type 2 activity and neonatal birthweight in pregnancies complicated by asthma. Aust N Z J Obstet Gynaecol. 2006;46:136-140.
15. Osei-Kumah A, Smith R, Jurisica I, Caniggia I, Clifton VL. Sex-specific differences in placental global gene expression in pregnancies complicated by asthma. Placenta. 2011;32: 570-578.
16. Liggins GC, Howie RN. A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants. Pediatrics. 1972; 50:515-525.
17. Roberts D, Dalziel S. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst Rev. 2006;3:CD004454.
18. Roberts D. Antenatal Corticosteroids to Reduce Neonatal Morbidity and Mortality. Green Top Guideline No. 7. London, UK: Royal College of Obstetricians and Gynecologists; 2010.
19. Lajic S, Nordenström A, Hirvikoski T. Long-term outcome of prenatal treatment of congenital adrenal hyperplasia. Endocr Dev. 2008;13:82-98.
20. Hirvikoski T, Nordenström A, Lindholm T, Lindblad F, Ritzén EM, Lajic S. Long-term follow-up of prenatally treated children at risk for congenital adrenal hyperplasia: does dexamethasone cause behavioural problems? Eur J Endocrinol. 2008;159:309-316.
21. Forest MG. Recent advances in the diagnosis and management of congenital adrenal hyperplasia due to 21-hydroxylase deficiency.HumReprod Update. 2004;10:469-485.
22. Newnham JP, Jobe AH. Should we be prescribing repeated courses of antenatal corticosteroids? Semin Fetal Neonatal Med. 2009;14:157-163.
23. Garite TJ, Kurtzman J, Maurel K, Clark R. Impact of a 'rescue course' of antenatal corticosteroids: a multicenter randomized placebo-controlled trial. Am J Obstet Gynecol. 2009;200:248.e1-e9.
24. Crowther CA, Harding JE. Repeat doses of prenatal corticosteroids for women at risk of preterm birth for preventing neonatal respiratory disease. Cochrane Database Syst Rev. 2007:CD003935.
25. Murphy KE, Willan AR, Hannah ME, et al. Effect of antenatal corticosteroids on fetal growth and gestational age at birth. Obstet Gynecol. 2012;119:917-923.
26. Long NM, Shasa DR, Ford SP, Nathanielsz PW. Growth and insulin dynamics in two generations of female offspring of mothers receiving a single course of synthetic glucocorticoids. Am J Obstet Gynecol. 2012;207:203.e1- e8.
27. Challis JR. Endocrine disorders in pregnancy: Stress responses in children after maternal glucocorticoids. Nat Rev Endocrinol. 2012;8:629-630.
28. Challis JR, Sloboda D, Matthews SG, et al. The fetal placental hypothalamic-pituitary-adrenal (HPA) axis, parturition and post natal health. Mol Cell Endocrinol. 2001; 185:135-144.
29. SlobodaDM,Challis JR, Moss TJ,NewnhamJP. Synthetic glucocorticoids: antenatal administration and long-term implications. Curr Pharm Des. 2005;11:1459-1472.
30. Kapoor A, Petropoulos S, Matthews SG. Fetal programming of hypothalamic-pituitary-adrenal (HPA) axis function and behavior by synthetic glucocorticoids. Brain Res Rev. 2008;57:586-595.
31. Magyar DM, Fridshal D, Elsner CW, et al. Time-trend analysis of plasma cortisol concentrations in the fetal sheep in relation to parturition. Endocrinology. 1980;107:155- 159.
32. Norman LJ, Lye SJ, Wlodek ME, Challis JR. Changes in pituitary responses to synthetic ovine corticotrophin releasing factor in fetal sheep. Can J Physiol Pharmacol. 1985;63:1398-1403.
33. Challis JR, Brooks AN. Maturation and activation of hypothalamic-pituitary adrenal function in fetal sheep. Endocr Rev. 1989;10:182-204.
34. MacIsaac RJ, Bell RJ, McDougall JG, Tregear GW, Wang X, Wintour EM. Development of the hypothalamic-pituitary-axis in the ovine fetus: ontogeny of action of ovine corticotropin-releasing factor. J Dev Physiol. 1985;7:329- 338.
35. Long NM, Ford SP, Nathanielsz PW. Multigenerational effects of fetal dexamethasone exposure on the hypothalamic-pituitary-adrenal axis of first- and second-generation female offspring. Am J Obstet Gynecol. 2013;208(3): 217.e1-e8.
36. Fowden AL, Li J, Forhead AJ. Glucocorticoids and the preparation for life after birth: are there long-term consequences of the life insurance? Proc Nutr Soc. 1998;57:113- 122.
37. Challis JR, Matthews SG, Gibb W, Lye SJ. Endocrine and paracrine regulation of birth at term and preterm. Endocr Rev. 2000;21:514-550.
38. Liggins GC. The role of cortisol in preparing the fetus for birth. Reprod Fertil Dev. 1994;6:141-150.
39. Sloboda DM, Newnham JP, Challis JR. Effects of repeated maternal betamethasone administration on growth and hypothalamic-pituitary-adrenal function of the ovine fetus at term. J Endocrinol. 2000;165:79-91.
40. SlobodaDM,NewnhamJP, Challis JR. Repeated maternal glucocorticoid administration and the developing liver in fetal sheep. J Endocrinol. 2002;175:535-543.
41. Sloboda DM, Moss TJ, Gurrin LC, Newnham JP, Challis JR. The effect of prenatal betamethasone administration on postnatal ovine hypothalamic-pituitary-adrenal function. J Endocrinol. 2002;172:71-81.
42. Hauser J, Dettling-Artho A, Pilloud S, et al. Effects of prenatal dexamethasone treatment on postnatal physical, endocrine, and social development in the common marmoset monkey. Endocrinology. 2007;148:1813-1822.
43. Franko KL, Forhead AJ, Fowden AL. Differential effects of prenatal stress and glucocorticoid administration on postnatal growth and glucose metabolism in rats. J Endocrinol. 2010;204:319-329.
44. O'Regan D, Kenyon CJ, Seckl JR, Holmes MC. Glucocorticoid exposure in late gestation in the rat permanently programs gender-specific differences in adult cardiovascular and metabolic physiology. Am J Physiol Endocrinol Metab. 2004;287:E863-E870.
45. Castañeda-Gutiérrez E, Pouteau E, Pescia G, Moulin J, Aprikian O, Macé K. The guinea pig as a model for metabolic programming of adiposity. Am J Clin Nutr. 2011; 94:1838S-1845S.
46. Armitage JA,KhanIY, Taylor PD, NathanielszPW,Poston L. Developmental programming of the metabolic syndrome by maternal nutritional imbalance: how strong is the evidence from experimental models in mammals? J Physiol. 2004;561:355-377.
47. Barker DJ, Osmond C, Golding J, Kuh D, Wadsworth ME. Growth in utero, blood pressure in childhood and adult life, and mortality from cardiovascular disease. BMJ. 1989;298:564-567.
48. Barker DJ, Osmond C, Simmonds SJ, Wield GA. The relation of small head circumference and thinness at birth to death from cardiovascular disease in adult life. BMJ. 1993; 306:422-426.
49. Barker DJ. Fetal origins of coronary heart disease. BMJ. 1995;311:171-174.
50. Barker DJ. Maternal and fetal origins of coronary heart disease. J R Coll Physicians Lond. 1994;28:544-551.
51. Barker DJ, HalesCN,FallCH,OsmondC, Phipps K, Clark PM. Type 2 (non-insulin-dependent) diabetes mellitus, hypertension and hyperlipidaemia (syndrome X): relation to reduced fetal growth. Diabetologia. 1993;36:62-67.
52. Barker DJ. Fetal programming of coronary heart disease. Trends Endocrinol Metab. 2002;13:364-368.
53. Dörner G, Plagemann A. Perinatal hyperinsulinism as possible predisposing factor for diabetes mellitus, obesity and enhanced cardiovascular risk in later life. Horm Metab Res. 1994;26:213-221.
54. Phillips DI, Barker DJ, Fall CH, et al. Elevated plasma cortisol concentrations: a link between low birth weight and the insulin resistance syndrome? J Clin Endocrinol Metab. 1998;83:757-760.
55. Cottrell EC, Seckl JR. Prenatal stress, glucocorticoids and the programming of adult disease. Front Behav Neurosci. 2009;3:19.
56. Seckl JR. Prenatal glucocorticoids and long-term programming. Eur J Endocrinol. 2004;151(Suppl 3):U49-U62.
57. Matthews SG, Owen D, Banjanin S, Andrews MH. Glucocorticoids, hypothalamo-pituitary-adrenal (HPA) development, and life after birth. Endocr Res. 2002;28:709- 718.
58. Challis JRG, Connor K, Matthews SG, et al. Development of the fetal hypothalamic-pituitary-Adrenal-placental axis: implications for postnatal health. In: Newnham JP, Ross MG,eds. Early Life Origins ofHumanHealth and Disease. Basel, Switzerland: Karger; 2009:89-99.
59. Matthews SG, Han X, Lu F, Challis JR. Developmental changes in the distribution of pro-opiomelanocortin and prolactin mRNA in the pituitary of the ovine fetus and lamb. J Mol Endocrinol. 1994;13:175-185.
60. Matthews SG, Challis J. Regulation of hypothalamo-pituitary-adrenocortical axis in fetal sheep. Trends Endocrinol Metab. 1996;7:239-246.
61. Sloboda DM, Moss TJ, Li S, et al. Prenatal betamethasone exposure results in pituitary-adrenal hyporesponsiveness in adult sheep.AmJ Physiol Endocrinol Metab. 2007;292: E61-E70.
62. Setiawan E, Jackson MF, MacDonald JF, Matthews SG. Effects of repeated prenatal glucocorticoid exposure on long-term potentiation in the juvenile guinea-pig hippocampus. J Physiol. 2007;581:1033-1042.
63. Owens PC, Owens JA, Lovelock M, et al. Restriction of placental growth in sheep enhances placental metabolism of fetalβ-endorphin-like immunoreactivity. J Dev Physiol. 1989;11:63-71.
64. McCabe L, Marash D, Li A, Matthews SG. Repeated antenatal glucocorticoid treatment decreases hypothalamic corticotropin releasing hormone mRNA but not corticosteroid receptor mRNA expression in the fetal guinea-pig brain. J Neuroendocrinol. 2001;13:425-431.
65. Sloboda DM, Moss TJ, Li S, Matthews SG, Challis JR, Newnham JP. Expression of glucocorticoid receptor, mineralocorticoid receptor, and 11β-hydroxysteroid dehydrogenase 1 and 2 in the fetal and postnatal ovine hippocampus: ontogeny and effects of prenatal glucocorticoid exposure. J Endocrinol. 2008;197:213-220.
66. Goland RS, Jozak S, Warren WB, Conwell IM, Stark RI, Tropper PJ. Elevated levels of umbilical cord plasma corticotropin-releasing hormone in growth-retarded fetuses. J Clin Endocrinol Metab. 1993;77:1174-1179.
67. Dodic M, Wintour EM. Effects of prolonged (48 h) infusion of cortisol on blood pressure, renal function and fetal fluids in the immature ovine foetus. Clin Exp Pharmacol Physiol. 1994;21:971-980.
68. Uno H, Lohmiller L, Thieme C, et al. Brain damage induced by prenatal exposure to dexamethasone in fetal rhesus macaques. I. Hippocampus. Brain Res Dev Brain Res. 1990;53:157-167.
69. Lindsay RS, Lindsay RM, Waddell BJ, Seckl JR. Prenatal glucocorticoid exposure leads to offspring hyperglycaemia in the rat: studies with the 11β-hydroxysteroid dehydrogenase inhibitor carbenoxolone. Diabetologia. 1996;39: 1299-1305.
70. Welberg LA, Seckl JR. Prenatal stress, glucocorticoids and the programming of the brain. J Neuroendocrinol. 2001; 13:113-128.
71. Weinstock M, Matlina E, Maor GI, Rosen H, McEwen BS. Prenatal stress selectively alters the reactivity of the hypothalamic-pituitary adrenal system in the female rat. Brain Res. 1992;595:195-200.
72. Levitt NS, Lambert EV, Woods D, Hales CN, Andrew R, Seckl JR. Impaired glucose tolerance and elevated blood pressure in low birth weight, nonobese, young South African adults: early programming of cortisol axis. J Clin Endocrinol Metab. 2000;85:4611-4618.
73. Reynolds RM, Walker BR, Syddall HE, Whorwood CB, Wood PJ, Phillips DI. Elevated plasma cortisol in glucoseintolerant men: differences in responses to glucose and habituation to venepuncture. J Clin Endocrinol Metab. 2001; 86:1149-1153.
74. Gluckman PD, Hanson MA. Living with the past: evolution, development, and patterns of disease. Science. 2004; 305:1733-1736.
75. Barker DJ, Osmond C. Infant mortality, childhood nutrition, and ischaemic heart disease in England and Wales. Lancet. 1986;1:1077-1081.
76. Dörner G. 1974 Perinatal hormone levels and brain organization. In: Stumpf WE, Grant LD, eds. Anatomical Neuroendocrinology. Basel, Switzerland: Karger; 1974:245- 252.
77. Schellong K, Schulz S, Harder T, Plagemann. A Birth weight and long-term overweight risk: systematic review and a meta-analysis including 643,902 persons from 66 studies and 26 countries globally. PLoS One. 2012;7: e47776.
78. Liu D, Diorio J, Tannenbaum B, et al. Maternal care, hippocampal glucocorticoid receptors, and hypothalamic-pituitary-adrenal responses to stress. Science. 1997;277: 1659-1662.
79. Meaney MJ, Szyf M, Seckl JR. Epigenetic mechanisms of perinatal programming of hypothalamic-pituitary-adrenal function and health. Trends Mol Med. 2007;13:269-277.
80. Szyf M, Meaney MJ. Epigenetics, behaviour, and health. Allergy Asthma Clin Immunol. 2008;4:37-49.
81. Szyf M, McGowan P, Meaney MJ. The social environment and the epigenome. Environ Mol Mutagen. 2008;49:46- 60.
82. Weaver IC, Cervoni N, Champagne FA, et al. Epigenetic programming by maternal behavior. Nat Neurosci. 2004; 7:847-854.
83. Meaney MJ, Ferguson-Smith AC. Epigenetic regulation of the neural transcriptome: the meaning of the marks. Nat Neurosci. 2010;13:1313-1318.
84. Murgatroyd C, Patchev AV, Wu Y, et al. Dynamic DNA methylation programs persistent adverse effects of earlylife stress. Nat Neurosci. 2009;12:1559-1566.
85. Meany MJ, Weaver IC, Wu T, et al. Maternal programming of glucocorticoid receptor expression and HPA responses to stress through DNA methylation in the rat. In: HodgsonDM,Coe CL, eds. Perinatal Programming. Early Life Determinants of Adult Health and Disease. London, UK: Taylor & Francis; 2006:309-324.
86. Champagne FA, Francis DD, Mar A, Meaney MJ. Variations in maternal care in the rat as a mediating influence for the effects of environment on development. Physiol Behav. 2003;79:359-371.
87. Champagne FA, Curley JP, Keverne EB, Bateson PP. Natural variations in postpartum maternal care in inbred and outbred mice. Physiol Behav. 2007;91:325-334.
88. Crowley P. Prophylactic corticosteroids for preterm birth. Cochrane Database Syst Rev. 2000;2:CD000065.
89. Mayhew TM, Jenkins H, Todd B, Clifton VL. Maternal asthma and placental morphometry: effects of severity, treatment and fetal sex. Placenta. 2008;29:366-373.
90. Murphy VE, Gibson PG, Giles WB, et al. Maternal asthma is associated with reduced female fetal growth.AmJ Respir Crit Care Med. 2003;168:1317-1323.
91. Dodic M, Tersteeg M, Jefferies A, Wintour EM, Moritz K. Prolonged low-dose dexamethasone treatment, in early gestation, does not alter blood pressure or renal function in adult sheep. J Endocrinol. 2003;179:275-280.
92. Ritzén EM. Prenatal dexamethasone treatment of fetuses at risk for congenital adrenal hyperplasia: benefits and concerns. Semin Neonatol. 2001;6:357-362.
93. Liggins GC. Premature delivery of foetal lambs infused with glucocorticoids. J Endocrinol. 1969;45:515-523.
94. Pugeat MM, Dunn JF, Nisula BC. Transport of steroid hormones: interaction of 70 drugs with testosterone-binding globulin and corticosteroid-binding globulin in human plasma. J Clin Endocrinol Metab. 1981;53:69-75.
95. Siebe H, Baude G, Lichtenstein I, et al. Metabolism of dexamethasone: sites and activity in mammalian tissues. Ren Physiol Biochem. 1993;16:79-88.
96. Kari MA, Hallman M, Eronen M, et al. Prenatal dexamethasone treatment in conjunction with rescue therapy of human surfactant: a randomized placebo-controlled multicenter study. Pediatrics. 1994;93:730-736.
97. Ballard RA, Ballard PL. Antenatal hormone therapy for improving the outcome of the preterm infant. J Perinatol. 1996;16:390-396.
98. Anyaegbunam WI, Adetona AB. Use of antenatal corticosteroids for fetal maturation in preterm infants. Am Fam Physician. 1997;56:1093-1096.
99. Ee L, Hagan R, Evans S, French N. Antenatal steroids, condition at birth and respiratory morbidity and mortality in very preterm infants. J Paediatr Child Health. 1998;34: 377-383.
100. ACOG Committee on Obstetric Practice ACOG Committee Opinion No. 475: antenatal corticosteroid therapy for fetal maturation. Obstet Gynecol. 2011;117:422-424.
101. French NP, Hagan R, Evans SF, Mullan A, Newnham JP. Repeated antenatal corticosteroids: effects on cerebral palsy and childhood behavior. Am J Obstet Gynecol. 2004;190:588-595.
102. Seckl JR, Meaney MJ. Glucocorticoid "programming" and PTSD risk. Ann N Y Acad Sci. 2006;1071:351-378.
103. Niwa F, Kawai M, Kanazawa H, et al. Limited response to CRH stimulation tests at two weeks of age in preterm infants born at less than 30 weeks of gestational age. Clin Endocrinol (Oxf). 2013;78:724-729.
104. McKinlay CJ, Crowther CA, Middleton P, Harding JE. Repeat antenatal glucocorticoids for women at risk of preterm birth: a Cochrane Systematic Review. Am J Obstet Gynecol. 2012;206:187-194.
105. Dalziel SR, Rea HH, Walker NK, Pet al. Long term effects of antenatal betamethasone on lung function: 30 year follow up of a randomised controlled trial. Thorax. 2006;61: 678-683.
106. Dalziel SR, Liang A, Parag V, Rodgers A, Harding JE. Blood pressure at 6 years of age after prenatal exposure to betamethasone: follow-up results of a randomized, controlled trial. Pediatrics. 2004;114:e373-e377.
107. Dalziel SR, Walker NK, Parag V, et al. Cardiovascular risk factors after antenatal exposure to betamethasone: 30-year follow-up of a randomised controlled trial. Lancet. 2005; 365:1856-1862.
108. Dalziel SR, Lim VK, Lambert A, et al. Antenatal exposure to betamethasone: psychological functioning and health related quality of life 31 years after inclusion in randomised controlled trial. BMJ. 2005;331:665.
109. Dalziel SR, Fenwick S, Cundy T, et al. Peak bone mass after exposure to antenatal betamethasone and prematurity: follow-up of a randomized controlled trial. J Bone Miner Res. 2006;21:1175-1186.
110. Dalziel SR, Parag V, Rodgers A, Harding JE. Cardiovascular risk factors at age 30 following pre-term birth. Int J Epidemiol. 2007;36:907-915.
111. Finken MJ, Keijzer-Veen MG, Dekker FW, et al. Dutch POPS-19 Collaborative Study Group. Antenatal glucocorticoid treatment is not associated with long-term metabolic risks in individuals born before 32 weeks of gestation. Arch Dis Child Fetal Neonatal Ed. 2008;93:F442-F447.
112. Kelly BA, Lewandowski AJ, Worton SA, et al. Antenatal glucocorticoid exposure and long-term alterations in aortic function and glucose metabolism. Pediatrics. 2012;129: e1282-e1290.
113. Brownfoot FC, Crowther CA, Middleton P. Different corticosteroids and regimens for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst Rev. 2008;4:CD006764.
114. Sotiriadis A, Makrydimas G, Papatheodorou S, Ioannidis JP. Corticosteroids for preventing neonatal respiratory morbidity after elective caesarean section at term. Cochrane Database Syst Rev. 2009;4:CD006614.
115. Reynolds RM, Seckl JR. Antenatal glucocorticoid treatment: are we doing harm to term babies? J Clin Endocrinol Metab. 2012;97:3457-3459.
116. Loehle M, Schwab M, Kadner S, Maner KM, Gilbert JS, Brenna JT, Ford SP, Nathanielsz PW, Nijland MJ. Doseresponse effects of betamethasone on maturation of the fetal sheep lung. Am J Obstet Gynecol. 2010;202:186.e1- e7.
117. McLaughlin KJ, Crowther CA, Walker N, Harding JE. Effects of a single course of corticosteroids given more than 7 days before birth: a systematic review.AustNZJObstet Gynaecol. 2003;43:101-106.
118. French NP, Hagan R, Evans SF, Godfrey M, Newnham JP. Repeated antenatal corticosteroids: size at birth and subsequent development. Am J Obstet Gynecol. 1999;180: 114-121.
119. Thorp JA, Jones PG, Knox E, Clark RH. Does antenatal corticosteroid therapy affect birth weight and head circumference? Obstet Gynecol. 2002;99:101-108.
120. Newnham JP, Moss TJ. Antenatal glucocorticoids and growth: single versus multiple doses in animal and human studies. Semin Neonatol. 2001;6:285-292.
121. Seckl JR. Glucocorticoids and small babies. Q J Med. 1994;87:259-262.
122. Bloom SL, Sheffield JS, McIntire DD, Leveno KJ. Antenatal dexamethasone and decreased birth weight. Obstet Gynecol. 2001;97:485-490.
123. Esplin MS, Fausett M, Smith S, et al. Multiple courses of antenatal steroids are associated with delay in long-term psychomotor development in children with birth weightβ 1500 grams. Am J Obstet Gynecol. 2000;182(1 part 2): S24.
124. Rodriguez JS, Zurcher NR, Keenan KE, Bartlett TQ, Nathanielsz PW, Nijland MJ. Prenatal betamethasone exposure has sex specific effects in reversal learning and attention in juvenile baboons.AmJ Obstet Gynecol. 2011;204: 545.e1-e10.
125. Schneider U, Arnscheidt C, Schwab M, Haueisen J, Seewald HJ, Schleussner E. Steroids that induce lung maturation acutely affect higher cortical function: a fetal magnetoencephalography study. Reprod Sci. 2011;18:99-106.
126. Crowther CA, McKinlay CJ, Middleton P, Harding JE. Repeat doses of prenatal corticosteroids for women at risk of preterm birth for improving neonatal health outcomes. Cochrane Database Syst Rev. 2011;6:CD003935.
127. Crowther CA, Aghajafari F, Askie LM, et al. PRECISE Study Group. Repeat prenatal corticosteroid prior to preterm birth: a systematic review and individual participant data meta-analysis for the PRECISE study group (prenatal repeat corticosteroid international IPD study group: assessing the effects using the best level of evidence)-study protocol. Syst Rev. 2012;1:12.
128. Seckl JR. Glucocorticoids, developmental 'programming' and the risk of affective dysfunction. Prog Brain Res. 2008; 167:17-34.
129. Seckl JR, Holmes MC. Mechanisms of disease: glucocorticoids, their placental metabolism and fetal 'programming' of adult pathophysiology. Nat Clin Pract Endocrinol Metab. 2007;3:479-488.
130. Bakker JM, Schmidt ED, Kroes H, et al. Effects of shortterm dexamethasone treatment during pregnancy on the development of the immune system and the hypothalamopituitary adrenal axis in the rat. J Neuroimmunol. 1995; 63:183-191.
131. Levitt NS, Lindsay RS, Holmes MC, Seckl JR. Dexamethasone in the last week of pregnancy attenuates hippocampal glucocorticoid receptor gene expression and elevates blood pressure in the adult offspring in the rat. Neuroendocrinology. 1996;64:412-418.
132. Nyirenda MJ, Lindsay RS, Kenyon CJ, Burchell A, Seckl JR. Glucocorticoid exposure in late gestation permanently programs rat hepatic phosphoenolpyruvate carboxykinase and glucocorticoid receptor expression and causes glucose intolerance in adult offspring. J Clin Invest. 1998;101: 2174-2181.
133. Newnham JP, Evans SF, Godfrey M, Huang W, Ikegami M, Jobe A. Maternal, but not fetal, administration of corticosteroids restricts fetal growth. J Matern Fetal Med. 1999;8:81-87.
134. Thakur A, SaseM,Lee JJ, Thakur V, Buchmiller TL. Effect of dexamethasone on insulin-like growth factor-1 expression in a rabbit model of growth retardation. J Pediatr Surg. 2000;35:898-904; discussion 904-895.
135. Johnson JW, Mitzner W, Beck JC, et al. Long-term effects of betamethasone on fetal development. Am J Obstet Gynecol. 1981;141:1053-1064.
136. Antonow-Schlorke I, Schwab M, Li C, Nathanielsz PW. Glucocorticoid exposure at the dose used clinically alters cytoskeletal proteins and presynaptic terminals in the fetal baboon brain. J Physiol. 2003;547:117-123.
137. Antonow-Schlorke I, Ebert M, Li C, et al. Lack of effect of antenatal glucocorticoid therapy in the fetal baboon on cerebral cortical glucose transporter proteins. J Med Primatol. 2007;36:17-20.
138. IkegamiM,Jobe AH,NewnhamJ, PolkDH,Willet KE, Sly P. Repetitive prenatal glucocorticoids improve lung function and decrease growth in preterm lambs. Am J Respir Crit Care Med. 1997;156:178-184.
139. Moss TJ, Sloboda DM, Gurrin LC, Harding R, Challis JR, Newnham JP. Programming effects in sheep of prenatal growth restriction and glucocorticoid exposure. Am J Physiol Regul Integr Comp Physiol. 2001;281:R960- R970.
140. Huang WL, Beazley LD, Quinlivan JA, Evans SF, Newnham JP, Dunlop SA. Effect of corticosteroids on brain growth in fetal sheep. Obstet Gynecol. 1999;94:213-218.
141. Moss TJ, Doherty DA, Nitsos I, Sloboda DM, Harding R, Newnham JP. Effects into adulthood of single or repeated antenatal corticosteroids in sheep. Am J Obstet Gynecol. 2005;192:146-152.
142. Dunlop SA, ArcherMA,Quinlivan JA, Beazley LD, Newnham JP. Repeated prenatal corticosteroids delay myelination in the ovine central nervous system. J Matern Fetal Med. 1997;6:309-313.
143. de Vries A, Holmes MC, Heijnis A, et al. Prenatal dexamethasone exposure induces changes in nonhuman primate offspring cardiometabolic and hypothalamic-pituitary-adrenal axis function. J Clin Invest. 2007;117:1058- 1067.
144. Welberg LA, Seckl JR, Holmes MC. Inhibition of 11β-hydroxysteroid dehydrogenase, the foeto-placental barrier to maternal glucocorticoids, permanently programs amygdala GR mRNA expression and anxiety-like behaviour in the offspring. Eur J Neurosci. 2000;12:1047-1054.
145. Waffarn F, Davis EP. Effects of antenatal corticosteroids on the hypothalamic-pituitary-adrenocortical axis of the fetus and newborn: experimental findings and clinical considerations. Am J Obstet Gynecol. 2012;207:446-454.
146. Tegethoff M, Pryce C, Meinlschmidt G. Effects of intrauterine exposure to synthetic glucocorticoids on fetal, newborn, and infant hypothalamic-pituitary-adrenal axis function in humans: a systematic review. Endocr Rev. 2009;30:753-789.
147. Yehuda R, Engel SM, Brand SR, Seckl J, Marcus SM, Berkowitz GS. Transgenerational effects of posttraumatic stress disorder in babies of mothers exposed to the World Trade Center attacks during pregnancy. J Clin Endocrinol Metab. 2005;90:4115-4118.
148. Ballard PL, Granberg P, Ballard RA. Glucocorticoid levels in maternal and cord serum after prenatal betamethasone therapy to prevent respiratory distress syndrome. J Clin Invest. 1975;56:1548-1554.
149. Kajantie E, Raivio T, Jänne OA, Hovi P, Dunkel L, Andersson S. Circulating glucocorticoid bioactivity in the preterm newborn after antenatal betamethasone treatment. J Clin Endocrinol Metab. 2004;89:3999-4003.
150. Marinoni E, Korebrits C, Di Iorio R, Cosmi EV, Challis JR. Effect of betamethasone in vivo on placental corticotropinreleasing hormone in human pregnancy. Am J Obstet Gynecol. 1998;178:770-778.
151. Nykänen P, Raivio T, Heinonen K, Jänne OA, Voutilainen R. Circulating glucocorticoid bioactivity and serum cortisol concentrations in premature infants: the influence of exogenous glucocorticoids and clinical factors. Eur J Endocrinol. 2007;156:577-583.
152. Ballard PL, Gluckman PD, Liggins GC, Kaplan SL, Grumbach MM. Steroid and growth hormone levels in premature infants after prenatal betamethasone therapy to prevent respiratory distress syndrome. Pediatr Res. 1980; 14:122-127.
153. Davis EP, Townsend EL, Gunnar MR, et al. Antenatal betamethasone treatment has a persisting influence on infant HPA axis regulation. J Perinatol. 2006;26:147-153.
154. Schäffer L, Luzi F, Burkhardt T, Rauh M, Beinder E. Antenatal betamethasone administration alters stress physiology in healthy neonates. Obstet Gynecol. 2009;113: 1082-1088.
155. Davis EP, Waffarn F, Sandman CA. Prenatal treatment with glucocorticoids sensitizes the hpa axis response to stress among full-term infants. Dev Psychobiol. 2011;53: 175-183.
156. Ashwood PJ, Crowther CA, Willson KJ, et al. Neonatal adrenal function after repeat dose prenatal corticosteroids: a randomized controlled trial.AmJ Obstet Gynecol. 2006; 194:861-867.
157. Alexander N, Rosenlöcher F, Stalder T, et al. Impact of antenatal synthetic glucocorticoid exposure on endocrine stress reactivity in term-born children. J Clin Endocrinol Metab. 2012;97:3538-3544.
158. Uno H, Eisele S, Sakai A, et al. Neurotoxicity of glucocorticoids in the primate brain. Horm Behav. 1994;28:336- 348.
159. Dunn E, Kapoor A, Leen J, Matthews SG. Prenatal synthetic glucocorticoid exposure alters hypothalamic-pituitary-adrenal regulation and pregnancy outcomes in mature female guinea pigs. J Physiol. 2010;588:887-899.
160. Segar JL, Lumbers ER, Nuyt AM, Smith OJ, Robillard JE. Effect of antenatal glucocorticoids on sympathetic nerve activity at birth in preterm sheep.AmJ Physiol. 1998;274: R160-R167.
161. Braun T, Li S, SlobodaDM,et al. Effects of maternal dexamethasone treatment in early pregnancy on pituitary-adrenal axis in fetal sheep. Endocrinology. 2009;150:5466- 5477.
162. Jobe AH. Postnatal corticosteroids for preterm infants-do what we say, not what we do. N Engl J Med. 2004;350: 1349-1351.
163. Antonow-Schlorke I, Helgert A, Gey C, et al. Adverse effects of antenatal glucocorticoids on cerebral myelination in sheep. Obstet Gynecol. 2009;113:142-151.
164. Liu L, Li A, Matthews SG. Maternal glucocorticoid treatment programs HPA regulation in adult offspring: sexspecific effects. Am J Physiol Endocrinol Metab. 2001; 280:E729-E739.
165. Price WA, Stiles AD, Moats-Staats BM, D'Ercole AJ. Gene expression of insulin-like growth factors (IGFs), the type 1 IGF receptor, and IGF-binding proteins in dexamethasoneinduced fetal growth retardation. Endocrinology. 1992; 130:1424-1432.
166. Li J, Saunders JC, Gilmour RS, Silver M, Fowden AL. Insulin-like growth factor-II messenger ribonucleic acid expression in fetal tissues of the sheep during late gestation: effects of cortisol. Endocrinology. 1993;132:2083-2089.
167. Gatford KL, Owens JA, Li S, et al. Repeated betamethasone treatment of pregnant sheep programs persistent reductions in circulating IGF-I and IGF-binding proteins in progeny. Am J Physiol Endocrinol Metab. 2008;295: E170-E178
168. Fowden AL. The insulin-like growth factors and feto-placental growth. Placenta. 2003;24:803-812.
169. Lassarre C, Hardouin S, Daffos F, Forestier F, Frankenne F, Binoux M. Serum insulin-like growth factors and insulin-like growth factor binding proteins in the human fetus. Relationships with growth in normal subjects and in subjects with intrauterine growth retardation. Pediatr Res. 1991;29:219-225.
170. Jensen EC, Gallaher BW, Breier BH, Harding JE. The effect of a chronic maternal cortisol infusion on the lategestation fetal sheep. J Endocrinol. 2002;174:27-36.
171. Mohan S, Baylink DJ. IGF-binding proteins are multifunctional and act via IGF-dependent and -independent mechanisms. J Endocrinol. 2002;175:19-31.
172. MosierHDJr, Spencer EM, Dearden LC, Jansons RA. The effect of glucocorticoids on plasma insulin-like growth factor I concentration in the rat fetus. Pediatr Res. 1987;22: 92-95.
173. Baker J, Liu JP, Robertson EJ, Efstratiadis A. Role of insulin-like growth factors in embryonic and postnatal growth. Cell. 1993;75:73-82.
174. Ahmad I, Beharry KD, Valencia AM, et al. Influence of a single course of antenatal betamethasone on the maternalfetal insulin-IGF-GH axis in singleton pregnancies. Growth Horm IGF Res. 2006;16:267-275.
175. Verhaeghe J, Van Herck E, Billen J, Moerman P, Van Assche FA, Giudice LC. Regulation of insulin-like growth factor-I and insulin-like growth factor binding protein-1 concentrations in preterm fetuses.AmJ Obstet Gynecol. 2003; 188:485-491.
176. Kajantie E, Hytinantti T, Koistinen R, et al. Markers of type I and type III collagen turnover, insulin-like growth factors, and their binding proteins in cord plasma of small premature infants: relationships with fetal growth, gestational age, preeclampsia, and antenatal glucocorticoid treatment. Pediatr Res. 2001;49:481-489.
177. Hill D. Fetal programming of the pancreatic cells and the implications for postnatal diabetes. Semin Neonatol. 1999;4:99-113.
178. Cox DB. The effect of maternal dexamethasone during early pregnancy on fetal growth, development and the control of glucose homeostasis. J Soc Gynecol Invest. 1999; 6(Suppl 1):251.
179. Kotelevtsev Y, Holmes MC, Burchell A, et al. 11β-Hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress. Proc Natl Acad Sci U S A. 1997;94:14924-14929.
180. Subtil D, Tiberghien P, Devos P, et al. Immediate and delayed effects of antenatal corticosteroids on fetal heart rate: a randomized trial that compares betamethasone acetate and phosphate, betamethasone phosphate, and dexamethasone. Am J Obstet Gynecol. 2003;188:524-531.
181. Fowden AL, Forhead AJ, Coan PM, Burton GJ. The placenta and intrauterine programming. J Neuroendocrinol. 2008;20:439-450.
182. Jansson T, Powell TL. Role of the placenta in fetal programming: underlying mechanisms and potential interventional approaches. Clin Sci (Lond). 2007;113:1-13.
183. Jansson T, Powell TL. Placental nutrient transfer and fetal growth. Nutrition. 2000;16:500-502.
184. Jansson T, Powell TL. IFPA Award in Placentology Lecture. Human placental transport in altered fetal growth: does the placenta function as a nutrient sensor? A review. Placenta. 2005;27(Suppl A):S91-S97.
185. Myatt L. Placental adaptive responses and fetal programming. J Physiol. 2006;572:25-30.
186. FowdenAL, Forhead AJ. Hormonesas epigenetic signals in developmental programming. Exp Physiol. 2009;94:607- 625.
187. Seckl JR, Cleasby M, Nyirenda MJ. Glucocorticoids, 11β-hydroxysteroid dehydrogenase, and fetal programming. Kidney Int. 2000;57:1412-1417.
188. Challis JR, Bloomfield FH, Bocking AD, et al. Fetal signals and parturition. J Obstet Gynaecol Res. 2005;31:492- 499.
189. Ward IL, Weisz J. Differential effects of maternal stress on circulating levels of corticosterone, progesterone, and testosterone in male and female rat fetuses and their mothers. Endocrinology. 1984;114:1635-1644.
190. American College of Obstetricians and Gynecologists Committee on Obstetric PracticeACOGCommittee Opinion No. 402: antenatal corticosteroid therapy for fetal maturation. Obstet Gynecol 2008;111:805-807.
191. Hennessy DP, Coghlan JP, Hardy KJ, Scoggins BA, Wintour EM. The origin of cortisol in the blood of fetal sheep. J Endocrinol. 1982;95:71-79.
192. Seckl JR. Glucocorticoids, feto-placental 11β-hydroxysteroid dehydrogenase type 2, and the early life origins of adult disease. Steroids. 1997;62:89-94.
193. Seckl JR, Benediktsson R, Lindsay RS, Brown RW. Placental 11β-hydroxysteroid dehydrogenase and the programming of hypertension. J Steroid Biochem Mol Biol. 1995;55:447-455.
194. Edwards CR, Benediktsson R, Lindsay RS, Seckl JR. Dysfunction of placental glucocorticoid barrier: link between fetal environment and adult hypertension? Lancet. 1993; 341:355-357.
195. Stewart PM, Murry BA, Mason JI. Type 2 11β-hydroxysteroid dehydrogenase in human fetal tissues. J Clin Endocrinol Metab. 1994;78:1529-1532.
196. Yang K, Matthews SG. Cellular localization of 11β-hydroxysteroid dehydrogenase 2 gene expression in the ovine adrenal gland. Mol Cell Endocrinol. 1995;111:R19-R23.
197. Brown RW, Chapman KE, Edwards CR, Seckl JR. Human placental 11β-hydroxysteroid dehydrogenase: evidence for and partial purification of a distinct NAD-dependent isoform. Endocrinology. 1993;132:2614-2621.
198. Waddell BJ, Benediktsson R, BrownRW,Seckl JR. Tissuespecific messenger ribonucleic acid expression of 11β-hydroxysteroid dehydrogenase types 1 and 2 and the glucocorticoid receptor within rat placenta suggests exquisite local control of glucocorticoid action. Endocrinology. 1998;139:1517-1523.
199. Brown RW, Diaz R, Robson AC, et al. The ontogeny of 11β-hydroxysteroid dehydrogenase type 2 and mineralocorticoid receptor gene expression reveal intricate control of glucocorticoid action in development. Endocrinology. 1996;137:794-797.
200. McTernan CL, Draper N, Nicholson H, et al. Reduced placental 11β-hydroxysteroid dehydrogenase type 2 mRNA levels in human pregnancies complicated by intrauterine growth restriction: an analysis of possible mechanisms. J Clin Endocrinol Metab. 2001;86:4979-4983.
201. Stewart PM, Rogerson FM, Mason JI. Type 2 11β-hydroxysteroid dehydrogenase messenger ribonucleic acid and activity in human placenta and fetal membranes: its relationship to birth weight and putative role in fetal adrenal steroidogenesis. J Clin Endocrinol Metab. 1995;80:885- 890.
202. Rogerson FM, Kayes KM, White PC. Variation in placental type 2 11β-hydroxysteroid dehydrogenase activity is not related to birth weight or placental weight. Mol Cell Endocrinol. 1997;128:103-109.
203. Mairesse J, Lesage J, Breton C, et al. Maternal stress alters endocrine function of the feto-placental unit in rats. Am J Physiol Endocrinol Metab. 2007;292:E1526-E1533.
204. Bertram CE, Hanson MA. Animal models and programming of the metabolic syndrome. Br Med Bull. 2001;60: 103-121.
205. Sarkar S, Tsai SW, Nguyen TT, Plevyak M, Padbury JF, Rubin LP. Inhibition of placental 11β-hydroxysteroid dehydrogenase type 2 by catecholamines via β-adrenergic signaling. Am J Physiol Regul Integr Comp Physiol. 2001; 281:R1966-R1974.
206. Tsugita M, Iwasaki Y, Nishiyama M, et al. Differential regulation of 11β-hydroxysteroid dehydrogenase type-1 and -2 gene transcription by proinflammatory cytokines in vascular smooth muscle cells. Life Sci. 2008;83:426-432.
207. Langley-Evans SC, Gardner DS, Jackson AA. Maternal protein restriction influences the programming of the rat hypothalamic-pituitary-adrenal axis. J Nutr. 1996;126: 1578-1585.
208. Alfaidy N, Gupta S, DeMarco C, Caniggia I, Challis JR. Oxygen regulation of placental 11β-hydroxysteroid dehydrogenase 2: physiological and pathological implications. J Clin Endocrinol Metab. 2002;87:4797-4805.
209. Saegusa H, Nakagawa Y, Liu YJ, Ohzeki T. Influence of placental 11β-hydroxysteroid dehydrogenase (11β-HSD) inhibition on glucose metabolism and 11β-HSDregulation in adult offspring of rats. Metabolism. 1999;48:1584- 1588.
210. Shams M, Kilby MD, Somerset DA, et al. 11Beta-hydroxysteroid dehydrogenase type 2 in human pregnancy and reduced expression in intrauterine growth restriction. Hum Reprod. 1998;13:799-804.
211. Dave-Sharma S, Wilson RC, Harbison MD, et al. Examination of genotype and phenotype relationships in 14 patients with apparent mineralocorticoid excess. J Clin Endocrinol Metab. 1998;83:2244-2254.
212. Monder C, Stewart PM, Lakshmi V, Valentino R, Burt D, Edwards CR. Licorice inhibits corticosteroid 11β-dehydrogenase of rat kidney and liver: in vivo and in vitro studies. Endocrinology. 1989;125:1046-1053.
213. Räikkönen K, Pesonen AK, Heinonen K, et al. Maternal licorice consumption and detrimental cognitive and psychiatric outcomes in children. Am J Epidemiol. 2009;170: 1137-1146.
214. Strandberg TE, Andersson S, Järvenpää AL, McKeigue PM. Preterm birth and licorice consumption during pregnancy. Am J Epidemiol. 2002;156:803-805.
215. Strandberg TE, Järvenpää AL, Vanhanen H, McKeigue PM. Birth outcome in relation to licorice consumption during pregnancy. Am J Epidemiol. 2001;153:1085-1088.
216. Murphy VE, Clifton VL. Alterations in human placental 11β-hydroxysteroid dehydrogenase type 1 and 2 with gestational age and labour. Placenta. 2003;24:739-744.
217. Petraglia F, Imperatore A, Challis JR. Neuroendocrine mechanisms in pregnancy and parturition. Endocr Rev. 2010;31:783-816.
218. Kurki T, Laatikainen T, Salminen-Lappalainen K, Ylikorkala O. Maternal plasma corticotrophin-releasing hormone-elevated in preterm labour but unaffected by indomethacin or nylidrin. Br J Obstet Gynaecol. 1991;98: 685-691.
219. Clifton VL, Read MA, Leitch IM, et al. Corticotropinreleasing hormone-induced vasodilatation in the human fetal-placental circulation: involvement of the nitric oxidecyclic guanosine 3β,5β-monophosphate-mediated pathway. J Clin Endocrinol Metab. 1995;80:2888-2893.
220. Imperatore A, Florio P, Torres PB, et al. Urocortin 2 and urocortin 3 are expressed by thehumanplacenta, deciduas, and fetal membranes. Am J Obstet Gynecol. 2006;195: 288-295.
221. Imperatore A, Rolfo A, Petraglia F, Challis JR, Caniggia I. Hypoxia and preeclampsia: increased expression of urocortin 2 and urocortin 3. Reprod Sci. 2010;17:833-843.
222. Imperatore A, Li W, Petraglia F, Challis JR. Urocortin 2 stimulates estradiol secretion from cultured human placental cells: an effect mediated by the type 2 corticotrophin-releasing hormone (CRH) receptor. Reprod Sci. 2009;16:551-558.
223. Schneider U, Fiedler A, Schröder B, et al. The effect of antenatal steroid treatment on fetal autonomic heart rate regulation revealed by fetal magnetocardiography (fMCG). Early Hum Dev. 2010;86:319-325.
224. Torricelli M, Novembri R, Bloise E, De Bonis M, Challis JR, Petraglia F. Changes in placentalCRH,urocortins, and CRH-receptor mRNA expression associated with preterm delivery and chorioamnionitis. J Clin Endocrinol Metab. 2011;96:534-540.
225. Godfrey KM. The role of the placenta in fetal programming: a review. Placenta. 2002;23(Suppl A):S20-S27.
226. Eriksson J, Forsén T, Tuomilehto J, Osmond C, Barker D. Fetal and childhood growth and hypertension in adult life. Hypertension. 2000;36:790-794.
227. Forsén T, Eriksson JG, Tuomilehto J, Teramo K, Osmond C, Barker DJ. Mother's weight in pregnancy and coronary heart disease in a cohort of Finnish men: follow up study. BMJ. 1997;315:837-840.
228. Barker DJ, Thornburg KL, Osmond C, Kajantie E, Eriksson JG. The surface area of the placenta and hypertension in the offspring in later life. Int J Dev Biol. 2010;54: 525-530.
229. Barker DJ, Bull AR, Osmond C, Simmonds SJ. Fetal and placental size and risk of hypertension in adult life. BMJ. 1990;301:259-262.
230. Barker DJP, Eriksson JG, Kajantie E, et al. The maternal and placental origins of chronic disease. In: Burton PJ, Barker DJP, Moffett A, Thornburg K, eds. The Placenta and Human Developmental Programming. Cambridge, UK: Cambridge University Press; 2011:5-13.
231. Baisden B, Sonne S, Joshi RM, Ganapathy V, Shekhawat PS. Antenatal dexamethasone treatment leads to changes in gene expression in a murine late placenta. Placenta. 2007;28:1082-1090.
232. Hahn T, Barth S, Graf R, et al. Placental glucose transporter expression is regulated by glucocorticoids. J Clin Endocrinol Metab. 1999;84:1445-1452.
233. Shafrir E, Barash V, Zederman R, Kissilevitz R, Diamant YZ. Modulation of fetal and placental metabolic pathways in response to maternal thyroid and glucocorticoid hormone excess. Isr J Med Sci. 1994;30:32-41.
234. McDonald TJ, Franko KL, Brown JM, Jenkins SL, Nathanielsz PW, Nijland MJ. Betamethasone in the last week of pregnancy causes fetal growth retardation but not adult hypertension in rats. J Soc Gynecol Investig. 2003;10: 469-473.
235. Hewitt DP, Mark PJ, Waddell BJ. Glucocorticoids prevent the normal increase in placental vascular endothelial growth factor expression and placental vascularity during late pregnancy in the rat. Endocrinology. 2006;147:5568- 5574.
236. Braun T, Li S, Moss TJ, et al. Maternal betamethasone administration reduces binucleate cell number and placental lactogen in sheep. J Endocrinol. 2007;194:337-347.
237. Kutzler MA, Ruane EK, Coksaygan T, Vincent SE, Nathanielsz PW. Effects of three courses of maternally administered dexamethasone at 0.7, 0.75, and 0.8 of gestation on prenatal and postnatal growth in sheep. Pediatrics. 2004;113:313-319.
238. Johnson JW, Mitzner W, LondonWT,Palmer AE, Scott R. Betamethasone and the rhesus fetus: multisystemic effects. Am J Obstet Gynecol. 1979;133:677-684.
239. Epstein MF, Farrell PM, Sparks JW, Pepe G, Driscoll SG, Chez RA. Maternal betamethasone and fetal growth and development in the monkey. Am J Obstet Gynecol. 1977; 127:261-263.
240. Vaughan GS, Forhead AJ, Fowden A. Glucocorticoids and placental programming. In: Burton PJ, Barker DJP, Moffett A, Thornburg K, eds. The Placenta and Human Developmental Programming. Cambridge, UK: Cambridge University Press; 2011:175-187.
241. Ward JW, Forhead AJ, Wooding FB, Fowden AL. Functional significance and cortisol dependence of the gross morphology of ovine placentomes during late gestation. Biol Reprod. 2006;74:137-145.
242. Braun T, Li S, Moss TJ, et al. Differential appearance of placentomes and expression of prostaglandin H synthase type 2 in placentome subtypes after betamethasone treatment of sheep late in gestation. Placenta. 2011;32:295- 303.
243. Ward JW, Wooding FB, Fowden AL. The effects of cortisol on the binucleate cell population in the ovine placenta during late gestation. Placenta. 2002;23:451-458.
244. Franko KL, Giussani DA, Forhead AJ, Fowden AL. Effects of dexamethasone on the glucogenic capacity of fetal, pregnant, and non-pregnant adult sheep. J Endocrinol. 2007; 192:67-73.
245. Warren WC, Liang R, Krivi GG, Siegel NR, Anthony RV. Purification and structural characterization of ovine placental lactogen. J Endocrinol. 1990;126:141-149.
246. Gluckman PD, Kaplan SL, Rudolph AM, GrumbachMM. Hormone ontogeny in the ovine fetus. II. Ovine chorionic somatomammotropin in mid- and late gestation in the fetal and maternal circulations. Endocrinology. 1979;104: 1828-1833.
247. Handwerger S, Freemark M. The roles of placental growth hormone and placental lactogen in the regulation ofhuman fetal growth and development. J Pediatr Endocrinol Metab. 2000;13:343-356.
248. Oliver MH, Harding JE, Breier BH, Evans PC, Gluckman PD. The nutritional regulation of circulating placental lactogen in fetal sheep. Pediatr Res. 1992;31:520-523.
249. Schoknecht PA, Currie WB, Bell AW. Kinetics of placental lactogen in mid- and late-gestation ovine fetuses. J Endocrinol. 1992;133:95-100.
250. Anthony RV, Pratt SL, Liang R, Holland MD. Placentalfetal hormonal interactions: impact on fetal growth. J Anim Sci. 1995;73:1861-1871.
251. Breier BH, Funk B, Surus A, et al. Characterization of ovine growth hormone (oGH) and ovine placental lactogen (oPL) binding to fetal and adult hepatic tissue in sheep: evidence that oGH and oPL interact with a common receptor. Endocrinology. 1994;135:919-928.
252. Kappes SM, Warren WC, Pratt SL, Liang R, Anthony RV. Quantification and cellular localization of ovine placental lactogen messenger ribonucleic acid expression during mid- and late gestation. Endocrinology. 1992;131:2829- 2838.
253. Wooding FB. Current topic: the synepitheliochorial placenta of ruminants: binucleate cell fusions and hormone production. Placenta. 1992;13:101-113.
254. Liggins GC. Adrenocortical-related maturational events in the fetus. Am J Obstet Gynecol. 1976;126:931-941.
255. Fowden AL, Ward JW, Wooding FP, Forhead AJ, Constancia M. Programming placental nutrient transport capacity. J Physiol. 2006;572:5-15.
256. Jobe AH, Wada N, Berry LM, Ikegami M, Ervin MG. Single and repetitive maternal glucocorticoid exposures reduce fetal growth in sheep. Am J Obstet Gynecol. 1998; 178:880-885.
257. Maltau JM, Stokke KT, Moe N. Effects of betamethasone on plasma levels of estriol, cortisol and HCS in late pregnancy. Acta Obstet Gynecol Scand. 1979;58:235-238.
258. Socias M, Wiest W, Schmidt R, Hiltmann WD, Höhn N. Behavior of estriol and HPL in serum during tocolysis with and without additional celestane administration [in German]. Arch Gynecol. 1979;228:157-158.
259. Lange AP, Anthonsen H. Serum levels of human placental lactogen during and after prenatal dexamethasone therapy. Acta Obstet Gynecol Scand. 1980;59:111-114.
260. Braun T, Husar A, Challis JR, Dudenhausen JW, Henrich W, Plagemann A, Sloboda DM. Growth restricting effects of a single course of antenatal betamethasone treatment and the role of human placental lactogen. Placenta. 2013; 34:407-415.
261. Burton GJ, Jauniaux E. The maternal circulation and placental shape. In: Burton PJ, Barker DJP, Moffett A, Thornburg K, eds. The Placenta andHumanDevelopmental Programming. Cambridge University Press; 2011:161-174.
262. Kadyrov M, Kosanke G, Kingdom J, Kaufmann P. Increased fetoplacental angiogenesis during first trimester in anaemic women. Lancet. 1998;352:1747-1749.
263. Lewis RM, Doherty CB, James LA, Burton GJ, Hales CN. Effects of maternal iron restriction on placental vascularization in the rat. Placenta. 2001;22:534-539.
264. Burton GJ, Reshetnikova OS, Milovanov AP, Teleshova OV. Stereological evaluation of vascular adaptations in human placental villi to differing forms of hypoxic stress. Placenta. 1996;17:49-55.
265. Reshetnikova OS, Burton GJ, Milovanov AP. Effects of hypobaric hypoxia on the fetoplacental unit: the morphometric diffusing capacity of the villous membrane at high altitude. Am J Obstet Gynecol. 1994;171:1560-1565.
266. Mayhew TM, Ohadike C, Baker PN, Crocker IP, Mitchell C, Ong SS. Stereological investigation of placental morphology in pregnancies complicated by pre-eclampsia with and without intrauterine growth restriction. Placenta. 2003;24:219-226.
267. Kingdom J, Huppertz B, Seaward G, Kaufmann P. Development of the placental villous tree and its consequences for fetal growth. Eur J Obstet Gynecol Reprod Biol. 2000; 92:35-43.
268. Thornburg KL, Louey S. Fetal roots of cardiac disease. Heart. 2005;91:867-868.
269. Anwar MA, Schwab M, Poston L, Nathanielsz PW. Betamethasone-mediated vascular dysfunction and changes in hematological profile in the ovine fetus. Am J Physiol. 1999;276:H1137-H1143.
270. Molnar J, Howe DC, Nijland MJ, Nathanielsz PW. Prenatal dexamethasone leads to both endothelial dysfunction and vasodilatory compensation in sheep. J Physiol. 2003; 547:61-66.
271. Docherty CC, Kalmar-Nagy J, Engelen M, et al. Effect of in vivo fetal infusion of dexamethasone at 0.75GAon fetal ovine resistance artery responses to ET-1. Am J Physiol Regul Integr Comp Physiol. 2001;281:R261-R268.
272. Forhead AJ, Gillespie CE, Fowden AL. Role of cortisol in the ontogenic control of pulmonary and renal angiotensinconverting enzyme in fetal sheep near term. J Physiol. 2000;526(Pt 2):409-416.
273. Grazul-Bilska AT, Borowicz PP, Johnson ML, et al. Placental development during early pregnancy in sheep: vascular growth and expression of angiogenic factors in maternal placenta. Reproduction. 2010;140:165-174.
274. Grazul-Bilska AT, Johnson ML, Borowicz PP, et al. Placental development during early pregnancy in sheep: cell proliferation, global methylation, and angiogenesis in the fetal placenta. Reproduction. 2011;141:529-540.
275. Wallerath T, Witte K, Schäfer SC, et al. Down-regulation of the expression of endothelial NO synthase is likely to contribute to glucocorticoid-mediated hypertension. Proc Natl Acad Sci U S A. 1999;96:13357-13362.
276. Aida K, Shi Q, Wang J, et al. The effects of betamethasone (BM) on endothelial nitric oxide synthase (eNOS) expression in adult baboon femoral arterial endothelial cells. J Steroid Biochem Mol Biol. 2004;91:219-224.
277. Aida K, Wang XL, Wang J, Li C, McDonald TJ, Nathanielsz PW. Effect of betamethasone administration to the pregnant baboon at 0.75 gestation on placental eNOS distribution and activity. Placenta. 2004;25:780-787.
278. Sherer DM, Abulafia O. Angiogenesis during implantation, and placental and early embryonic development. Placenta. 2001;22:1-13.
279. Gille J, Reisinger K, Westphal-Varghese B, Kaufmann R. Decreased mRNA stability as a mechanism of glucocorticoid-mediated inhibition of vascular endothelial growth factor gene expression by cultured keratinocytes. J Invest Dermatol. 2001;117:1581-1587.
280. Redmer DA, Aitken RP, Milne JS, Reynolds LP, Wallace JM. Influence of maternal nutrition on messenger RNA expression of placental angiogenic factors and their receptors at midgestation in adolescent sheep. Biol Reprod. 2005;72:1004-1009.
281. Reynolds LP, Borowicz PP, Vonnahme KA, et al. Animal models of placental angiogenesis. Placenta. 2005;26:689- 708.
282. Jones HN, Powell TL, Jansson T. Regulation of placental nutrient transport: a review. Placenta. 2007;28:763-774.
283. Jansson T, Cowley EA, Illsley NP. Cellular localization of glucose transporter messenger RNA in human placenta. Reprod Fertil Dev. 1995;7:1425-1430.
284. Jansson T. Amino acid transporters in the human placenta. Pediatr Res. 2001;49:141-147.
285. Jansson T, Ekstrand Y, Björn C, Wennergren M, Powell TL. Alterations in the activity of placental amino acid transporters in pregnancies complicated by diabetes. Diabetes. 2002;51:2214-2219.
286. Jansson N, Pettersson J, Haafiz A, et al. Down-regulation of placental transport of amino acids precedes the development of intrauterine growth restriction in rats fed a low protein diet. J Physiol. 2006;576:935-946.
287. Jansson T, Powell T. 2011 Placental amino acid transporters. In: Burton PJ, Barker DJP, Moffett A, Thornburg K, eds. The Placenta and Human Developmental Programming. Cambridge University Press; 2011:147-168.
288. Hauguel-de Mouzon S, Challier JC, Kacemi A, Caüzac M, Malek A, Girard J. The GLUT3 glucose transporter isoform is differentially expressed withinhumanplacental cell types. J Clin Endocrinol Metab. 1997;82:2689-2694.
289. Jansson T, Wennergren M, Powell TL. Placental glucose transport and GLUT 1 expression in insulin-dependent diabetes. Am J Obstet Gynecol. 1999;180:163-168.
290. Jansson T, Ekstrand Y, Wennergren M, Powell TL. Placental glucose transport in gestational diabetes mellitus. Am J Obstet Gynecol. 2001;184:111-116.
291. Langdown ML, Sugden MC. Enhanced placental GLUT1 and GLUT3 expression in dexamethasone-induced fetal growth retardation. Mol Cell Endocrinol. 2001;185:109- 117.
292. Wyrwoll CS, Seckl JR, Holmes MC. Altered placental function of 11β-hydroxysteroid dehydrogenase 2 knockout mice. Endocrinology. 2009;150:1287-1293.
293. Philipps AF, Holzman IR, Teng C, Battaglia FC. Tissue concentrations of free amino acids in term human placentas. Am J Obstet Gynecol. 1978;131:881-887.
294. Marconi AM, Paolini CL. Nutrient transport across the intrauterine growth-restricted placenta. Semin Perinatol. 2008;32:178-181.
295. Cleal JK, Lewis RM. The mechanisms and regulation of placental amino acid transport to the human foetus. J Neuroendocrinol. 2008;20:419-426.
296. Moe AJ. Placental amino acid transport. Am J Physiol. 1995;268:C1321-C1331.
297. Glazier JD, Cetin I, Perugino G, et al. Association between the activity of the system A amino acid transporter in the microvillous plasma membrane of the human placenta and severity of fetal compromise in intrauterine growth restriction. Pediatr Res. 1997;42:514-519.
298. Jansson T, Scholtbach V, Powell TL. Placental transport of leucine and lysine is reduced in intrauterine growth restriction. Pediatr Res. 1998;44:532-537.
299. Norberg S, Powell TL, Jansson T. Intrauterine growth restriction is associated with a reduced activity of placental taurine transporters. Pediatr Res. 1998;44:233-238.
300. Audette MC, Connor KL, Braun T, et al. Maternal glucocorticoid administartion in early pregnancy and the relationship between 11ßHSD2 mRNA in ovine placenta and fetal weight across gestation. Reprod Sci. 2008;15(Suppl): 273A.
301. Audette MC, Greenwood SL, Sibley CP, et al. Dexamethasone stimulates placental system A transport and trophoblast differentiation in term villous explants. Placenta. 2010;31:97-105.
302. Audette MC, Challis JR, Jones RL, Sibley CP, Matthews SG. Antenatal dexamethasone treatment in midgestation reduces system A-mediated transport in the late-gestation murine placenta. Endocrinology. 2011;152:3561-3570.
303. Garcia-Bournissen F, Feig DS, Koren G. Maternal-fetal transport of hypoglycaemic drugs. Clin Pharmacokinet. 2003;42:303-313.
304. Shiverick KT, SlikkerWJr, Rogerson SJ, Miller RK. Drugs and the placenta: a workshop report. Placenta. 2003; 24(Suppl A):S55-S59.
305. Ito S. Transplacental treatment of fetal tachycardia: implications of drug transporting proteins in placenta. Semin Perinatol. 2001;25:196-201.
306. Kleinman CS, Nehgme RA. Cardiac arrhythmias in the human fetus. Pediatr Cardiol. 2004;25:234-251.
307. Capparelli E, Rakhmanina N, Mirochnick M. Pharmacotherapy of perinatal HIV. Semin Fetal Neonatal Med. 2005;10:161-175.
308. Lee E, Maneno MK, Smith L, et al. National patterns of medication use during pregnancy. Pharmacoepidemiol Drug Saf. 2006;15:537-545.
309. Andrade SE, Raebel MA, Morse AN, et al. Use of prescription medications with a potential for fetal harm among pregnant women. Pharmacoepidemiol Drug Saf. 2006;15: 546-554.
310. Andrade SE, Gurwitz JH, Davis RL, et al. Prescription drug use in pregnancy. Am J Obstet Gynecol. 2004;191:398- 407.
311. Audus KL. Controlling drug delivery across the placenta. Eur J Pharm Sci. 1999;8:161-165.
312. Pacifici GM, Nottoli R. Placental transfer of drugs administered to the mother. Clin Pharmacokinet. 1995;28:235- 269.
313. Ceckova-Novotna M, Pavek P, Staud F. P-glycoprotein in the placenta: expression, localization, regulation and function. Reprod Toxicol. 2006;22:400-410.
314. Pasanen M. The expression and regulation of drug metabolism in human placenta. Adv Drug Deliv Rev. 1999;38: 81-97.
315. Syme MR, Paxton JW, Keelan JA. Drug transfer and metabolism by the human placenta. Clin Pharmacokinet. 2004;43:487-514.
316. Zhou SF. Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition. Xenobiotica. 2008;38:802-832.
317. Gil S, Saura R, Forestier F, Farinotti R. P-glycoprotein expression of the human placenta during pregnancy. Placenta. 2005;26:268-270.
318. Sun M, Kingdom J, Baczyk D, Lye SJ, Matthews SG, Gibb W. Expression of the multidrug resistance P-glycoprotein, (ABCB1 glycoprotein) in the human placenta decreases with advancing gestation. Placenta. 2006;27:602-609.
319. Rosenberg MF, Kamis AB, Callaghan R, Higgins CF, Ford RC. Three-dimensional structures of the mammalian multidrug resistance P-glycoprotein demonstrate major conformational changes in the transmembrane domains upon nucleotide binding. J Biol Chem. 2003;278:8294-8299.
320. Yeboah D, Sun M, Kingdom J, et al. Expression of breast cancer resistance protein (BCRP/ABCG2) in human placenta throughout gestation and at term before and after labor. Can J Physiol Pharmacol. 2006;84:1251-1258.
321. Polgar O, Robey RW, Bates SE. ABCG2: structure, function and role in drug response. Expert Opin Drug Metab Toxicol. 2008;4:1-15.
322. Doyle LA, Yang W, Abruzzo LV, et al. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci U S A. 1998;95:15665-15670.
323. Schinkel AH, Jonker JW. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv Drug Deliv Rev. 2003;55:3-29.
324. Iqbal M, Audette MC, Petropoulos S, Gibb W, Matthews SG. Placental drug transporters and their role in fetal protection. Placenta. 2012;33:137-142.
325. Hahnova-Cygalova L, CeckovaM,Staud F. Fetoprotective activity of breast cancer resistance protein (BCRP, ABCG2): expression and function throughout pregnancy. Drug Metab Rev. 2011;43:53-68.
326. Chang XB. A molecular understanding of ATP-dependent solute transport by multidrug resistance-associated protein MRP1. Cancer Metastasis Rev. 2007;26:15-37.
327. Haimeur A, Conseil G, Deeley RG, Cole SP. The MRPrelated and BCRP/ABCG2 multidrug resistance proteins: biology, substrate specificity and regulation. Curr Drug Metab. 2004;5:21-53.
328. Nagashige M, Ushigome F, Koyabu N, et al. Basal membrane localization of MRP1 in human placental trophoblast. Placenta. 2003;24:951-958.
329. Atkinson DE, Greenwood SL, Sibley CP, Glazier JD, Fairbairn LJ. Role of MDR1 and MRP1 in trophoblast cells, elucidated using retroviral gene transfer.AmJ Physiol Cell Physiol. 2003;285:C584-C591.
330. St-Pierre MV, Serrano MA, Macias RI, et al. Expression of members of the multidrug resistance protein family in human term placenta. Am J Physiol Regul Integr Comp Physiol. 2000;279:R1495-R1503.
331. Hodge LS, Tracy TS. Alterations in drug disposition during pregnancy: implications for drug therapy. Expert Opin Drug Metab Toxicol. 2007;3:557-571.
332. Petropoulos S, Gibb W, Matthews SG. Effect of glucocorticoids on regulation of placental multidrug resistance phosphoglycoprotein (P-gp) in the mouse. Placenta. 2010; 31:803-810.
333. Pavek P, Cerveny L, Svecova L, et al. Examination of glucocorticoid receptorβ-mediated transcriptional regulation of P-glycoprotein, CYP3A4, and CYP2C9 genes in placental trophoblast cell lines. Placenta. 2007;28:1004-1011.
334. Jansson T, Aye IL, Goberdhan DC. The emerging role of mTORC1 signaling in placental nutrient-sensing. Placenta. 2012;33(Suppl 2):e23- e29.
335. Kilberg MS, Shan J, Su N. ATF4-dependent transcription mediates signaling of amino acid limitation. Trends Endocrinol Metab. 2009;20:436-443.
336. Inoki K, Kim J, Guan KL. AMPK and mTOR in cellular energy homeostasis and drug targets.AnnuRev Pharmacol Toxicol. 2012;52:381-400.
337. Kaidanovich-Beilin O, Woodgett JR. GSK-3: functional insights from cell biology and animal models. Front Mol Neurosci. 2011;4:40.
338. Strakovsky RS, Zhou D, Pan YX. A low-protein diet during gestation in rats activates the placental mammalian amino acid response pathway and programs the growth capacity of offspring. J Nutr. 2010;140:2116-2120.
339. Rosario FJ, Jansson N, Kanai Y, Prasad PD, Powell TL, Jansson T. Maternal protein restriction in the rat inhibits placental insulin, mTOR, and STAT3 signaling and downregulates placental amino acid transporters. Endocrinology. 2011;152:1119-1129.
340. Ma Y, Zhu MJ, Uthlaut AB, et al. Upregulation of growth signaling and nutrient transporters in cotyledons of early to mid-gestational nutrient restricted ewes. Placenta. 2011; 32:255-263.
341. Zhu MJ, Du M, Nijland MJ, et al. Down-regulation of growth signaling pathways linked to a reduced cotyledonary vascularity in placentomes of over-nourished, obese pregnant ewes. Placenta. 2009;30:405-410.
342. Zhao Y, Altman BJ, Coloff JL, et al. Glycogen synthase kinase 3β and 3β mediate a glucose-sensitive antiapoptotic signaling pathway to stabilize Mcl-1. Mol Cell Biol. 2007; 27:4328-4339.
343. Yung HW, Calabrese S, Hynx D, et al. Evidence of placental translation inhibition and endoplasmic reticulum stress in the etiology of human intrauterine growth restriction. Am J Pathol. 2008;173:451-462.
344. Zoncu R, Efeyan A, Sabatini DM. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol. 2011;12:21-35.
345. Howell JJ, Manning BD. mTOR couples cellular nutrient sensing to organismal metabolic homeostasis. Trends Endocrinol Metab. 2011;22:94-102.
346. Alessi DR, Pearce LR, Garcia-Martinez JM. New insights into mTOR signaling: mTORC2 and beyond. Sci Signal. 2009;2:pe27.
347. Roos S, Powell TL, Jansson T. Placental mTOR links maternal nutrient availability to fetal growth. Biochem Soc Trans. 2009;37:295-298.
348. Roos S, Jansson N, Palmberg I, Säljö K, Powell TL, Jansson T. Mammalian target of rapamycin in the human placenta regulates leucine transport and is down-regulated in restricted fetal growth. J Physiol. 2007;582:449-459.
349. Street ME, Viani I, Ziveri MA, Volta C, Smerieri A, Bernasconi S. Impairment of insulin receptor signal transduction in placentas of intra-uterine growth-restricted newborns and its relationship with fetal growth. Eur J Endocrinol. 2011;164:45-52.
350. Laviola L, Perrini S, Belsanti G, et al. Intrauterine growth restriction in humans is associated with abnormalities in placental insulin-like growth factor signaling. Endocrinology. 2005;146:1498-1505.
351. Roos S, Lagerlöf O, Wennergren M, Powell TL, Jansson T. Regulation of amino acid transporters by glucose and growth factors in cultured primary human trophoblast cells is mediated by mTOR signaling. Am J Physiol Cell Physiol. 2009;297:C723-C731.
352. Roos S, Kanai Y, Prasad PD, Powell TL, Jansson T. Regulation of placental amino acid transporter activity by mammalian target of rapamycin. Am J Physiol Cell Physiol. 2009;296:C142-C150.
353. Arroyo JA, Brown LD, Galan HL. Placental mammalian target of rapamycin and related signaling pathways in an ovine model of intrauterine growth restriction. Am J Obstet Gynecol. 2009;201:616.e1-e7.
354. Rosario FJ, Schumacher MA, Jiang J, Kanai Y, Powell TL, Jansson T. Chronic maternal infusion of full-length adiponectin in pregnant mice down-regulates placental amino acid transporter activity and expression and decreases fetal growth. J Physiol. 2012;590:1495-1509.
355. Weichhart T, Haidinger M, Katholnig K, et al. Inhibition of mTOR blocks the anti-inflammatory effects of glucocorticoids in myeloid immune cells. Blood. 2011;117: 4273-4283.
356. McGhee NK, Jefferson LS, Kimball SR. Elevated corticosterone associated with food deprivation upregulates expression in rat skeletal muscle of the mTORC1 repressor, REDD1. J Nutr. 2009;139:828-834.
357. Mparmpakas D, Zachariades E, Goumenou A, Gidron Y, Karteris E. Placental DEPTOR as a stress sensor during pregnancy. Clin Sci (Lond). 2012;122:349-359.
358. Matthews SG, Phillips DI. Transgenerational inheritance of stress pathology. Exp Neurol. 2012;233:95-101.
359. Dunn GA, Bale TL. Maternal high-fat diet promotes body length increases and insulin insensitivity in second-generation mice. Endocrinology. 2009;150:4999-5009.
360. Drake AJ, Walker BR. The intergenerational effects of fetal programming: non-genomic mechanisms for the inheritance of low birth weight and cardiovascular risk. J Endocrinol. 2004;180:1-16.
361. Drake AJ, Walker BR, Seckl JR. Intergenerational consequences of fetal programming by in utero exposure to glucocorticoids in rats. Am J Physiol Regul Integr Comp Physiol. 2005;288:R34-R38.
362. Wehmer F, Porter RH, Scales B. Pre-mating and pregnancy stress in rats affects behaviour of grandpups. Nature. 1970; 227:622.
363. Bertram C, Khan O, Ohri S, Phillips DI, Matthews SG, Hanson MA. Transgenerational effects of prenatal nutrient restriction on cardiovascular and hypothalamic-pituitary-adrenal function. J Physiol. 2008;586:2217-2229.
364. SkinnerMK, AnwayMD,Savenkova MI, Gore AC, Crews D. Transgenerational epigenetic programming of the brain transcriptome and anxiety behavior. PLoS One. 2008;3: e3745.
365. Franklin TB, Russig H, Weiss IC, et al. Epigenetic transmission of the impact of early stress across generations. Biol Psychiatry. 2010;68:408-415.
366. Abdolmaleky HM, Cheng KH, Faraone SV, et al. Hypomethylation of MB-COMT promoter is a major risk factor for schizophrenia and bipolar disorder. Hum Mol Genet. 2006;15:3132-3145.
367. Alikhani-Koopaei R, Fouladkou F, Frey FJ, Frey BM. Epigenetic regulation of 11β-hydroxysteroid dehydrogenase type 2 expression. J Clin Invest. 2004;114:1146-1157.
368. Mueller BR, Bale TL. Sex-specific programming of offspring emotionality after stress early in pregnancy. J Neurosci. 2008;28:9055-9065.
369. Newell-Price J. Proopiomelanocortin gene expression and DNA methylation: implications for Cushing's syndrome and beyond. J Endocrinol. 2003;177:365-372.
370. Oberlander TF, Weinberg J, Papsdorf M, Grunau R, Misri S, Devlin AM. Prenatal exposure to maternal depression, neonatal methylation of human glucocorticoid receptor gene (NR3C1) and infant cortisol stress responses. Epigenetics. 2008;3:97-106.
371. Lussana F, Painter RC, OckeMC, Buller HR, Bossuyt PM, Roseboom TJ. Prenatal exposure to the Dutch famine is associated with a preference for fatty foods and a more atherogenic lipid profile. Am J Clin Nutr. 2008;88:1648- 1652.
372. Painter RC, Osmond C, Gluckman P, Hanson M, Phillips DI, Roseboom TJ. Transgenerational effects of prenatal exposure to the Dutch famine on neonatal adiposity and health in later life. BJOG. 2008;115:1243-1249.
373. Kaati G, Bygren LO, Edvinsson S. Cardiovascular and diabetes mortality determined by nutrition during parents' and grandparents' slow growth period. Eur J Hum Genet. 2002;10:682-688.
374. Kaati G, Bygren LO, Pembrey M, Sjöström M. Transgenerational response to nutrition, early life circumstances and longevity. Eur J Hum Genet. 2007;15:784-790.
375. ScharfMB,Black J, Hull S, Landin R, Farber R. Long-term nightly treatment with indiplon in adults with primary insomnia: results of a double-blind, placebo-controlled, 3-month study. Sleep. 2007;30:743-752.
376. Gluckman PD, Hanson MA, Beedle AS. Non-genomic transgenerational inheritance of disease risk. Bioessays. 2007;29:145-154.
377. Matthews SG, Phillips DI. Minireview: transgenerational inheritance of the stress response: a new frontier in stress research. Endocrinology. 2010;151:7-13.
378. Sundrani DP, Chavan Gautam PM, Mehendale SS, Joshi SR. Altered metabolism of maternal micronutrients and omega 3 fatty acids epigenetically regulate matrix metalloproteinases in preterm pregnancy: a novel hypothesis. Med Hypotheses. 2011;77:878-883.
379. Novakovic B, Saffery R. The ever growing complexity of placental epigenetics: role in adverse pregnancy outcomes and fetal programming. Placenta. 2012;33:959-970.
380. Nelissen EC, van Montfoort AP, Dumoulin JC, Evers JL. Epigenetics and the placenta. Hum Reprod Update. 2011; 17:397-417.
381. Wilhelm-Benartzi CS, Houseman EA, Maccani MA, et al. In utero exposures, infant growth, and DNA methylation of repetitive elements and developmentally related genes in human placenta. Environ Health Perspect. 2012;120: 296-302.
382. Jaenisch R, Bird A. Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nat Genet. 2003;33(Suppl):245-254.
383. Gabory A, Ferry L, Fajardy I, et al. Maternal diets trigger sex-specific divergent trajectories of gene expression and epigenetic systems in mouse placenta. PLoS One. 2012;7: e47986.
384. Gallou-Kabani C, Gabory A, Tost J, et al. Sex- and dietspecific changes of imprinted gene expression and DNA methylation in mouse placenta under a high-fat diet. PLoS One. 2010;5:e14398.
385. Filiberto AC, Maccani MA, Koestler D, et al. Birthweight is associated with DNA promoter methylation of the glucocorticoid receptor in human placenta. Epigenetics. 2011;6:566-572.
386. Marsit CJ, Lambertini L, Maccani MA, et al. Placentaimprinted gene expression association of infant neurobehavior. J Pediatr. 2012;160:854-860.e2.
387. Marsit CJ, MaccaniMA,Padbury JF, LesterBM. Placental 11-β hydroxysteroid dehydrogenase methylation is associated with newborn growth and a measure of neurobehavioral outcome. PLoS One. 2012;7:e33794.
388. Jiang X, Yan J, West AA, et al. Maternal choline intake alters the epigenetic state of fetal cortisol-regulating genes in humans. FASEB J. 2012;26:3563-3574.
389. Downing C, Johnson TE, Larson C, et al. Subtle decreases inDNAmethylation and gene expression at the mouse Igf2 locus following prenatal alcohol exposure: effects of a methyl-supplemented diet. Alcohol. 2011;45:65-71.
390. Suter M, Ma J, Harris A, et al. Maternal tobacco use modestly alters correlated epigenome-wide placental DNA methylation and gene expression. Epigenetics. 2011;6: 1284-1294.
391. SuterM,Abramovici A, Showalter L, et al. In utero tobacco exposure epigenetically modifies placental CYP1A1 expression. Metabolism. 2010;59:1481-1490.
392. Banister CE, Koestler DC, Maccani MA, Padbury JF, Houseman EA, Marsit CJ. Infant growth restriction is associated with distinct patterns of DNA methylation in human placentas. Epigenetics. 2011;6:920-927.
393. Ferreira JC, Choufani S, Grafodatskaya D, et al. WNT2 promoter methylation in human placenta is associated with low birthweight percentile in the neonate. Epigenetics. 2011;6:440-449.
394. Bromer C, Marsit CJ, Armstrong DA, Padbury JF, Lester B. Genetic and epigenetic variation of the glucocorticoid receptor (NR3C1) in placenta and infant neurobehavior. Dev Psychobiol. 2013;55:673-683.
395. Foix-L'helias L, Baud O, Lenclen R, Kaminski M, Lacaze-Masmonteil T. Benefit of antenatal glucocorticoids according to the cause of very premature birth. Arch Dis Child Fetal Neonatal Ed. 2005;90:F46-F48.
396. Jobe AH, Polk D, Ikegami M, et al. Lung responses to ultrasound-guided fetal treatments with corticosteroids in preterm lambs. J Appl Physiol. 1993;75:2099-2105.
397. Moïse AA, WeardenME,Kozinetz CA, Gest AL, Welty SE, Hansen TN. Antenatal steroids are associated with less need for blood pressure support in extremely premature infants. Pediatrics. 1995;95:845-850.
398. Sinclair JC. Meta-analysis of randomized controlled trials of antenatal corticosteroid for the prevention of respiratory distress syndrome: discussion. Am J Obstet Gynecol. 1995;173:335-344.
399. Ment LR, Oh W, Ehrenkranz RA, Philip AG, Duncan CC, Makuch RW. Antenatal steroids, delivery mode, and intraventricular hemorrhage in preterm infants.AmJ Obstet Gynecol. 1995;172:795-800.
400. Canterino JC, Verma U, Visintainer PF, Elimian A, Klein SA, Tejani N. Antenatal steroids and neonatal periventricular leukomalacia. Obstet Gynecol. 2001;97:135-139.
401. Vohr BR, Wright LL, Poole WK, McDonald SA. Neurodevelopmental outcomes of extremely low birth weight infantsβ32 weeks' gestation between 1993 and 1998. Pediatrics. 2005;116:635-643.
402. Elimian A, Verma U, Canterino J, Shah J, Visintainer P, Tejani N. Effectiveness of antenatal steroids in obstetric subgroups. Obstet Gynecol. 1999;93:174-179.
403. SchaapAH,Wolf H, BruinseHW,et al. Effects of antenatal corticosteroid administration on mortality and long-term morbidity in early preterm, growth-restricted infants. Obstet Gynecol. 2001;97:954-960.
404. Arad I, Durkin MS, Hinton VJ, et al. Long-term cognitive benefits of antenatal corticosteroids for prematurely born children with cranial ultrasound abnormalities. Am J Obstet Gynecol. 2002;186:818-825.
405. Tabor BL, Rider ED, Ikegami M, Jobe AH, Lewis JF. Dose effects of antenatal corticosteroids for induction of lung maturation in preterm rabbits. Am J Obstet Gynecol. 1991;164:675-681.
406. Wu FF, Momma K, Takao A. Cardiovascular and pulmonary effects of betamethasone during midtrimester on fetal rats. Fetal Diagn Ther. 1993;8:89-94.
407. Shelton SD, Boggess KA, Murtha AP, Groff AO, Herbert WN. Repeated fetal betamethasone treatment and birth weight and head circumference. Obstet Gynecol. 2001;97: 301-304.
408. Norberg H, Stålnacke J, Diaz Heijtz R, et al. Antenatal corticosteroids for preterm birth: dose-dependent reduction in birthweight, length and head circumference. Acta Paediatr. 2011;100:364-369.
409. Murphy KE, Hannah ME, Willan AR, et al. Multiple courses of antenatal corticosteroids for preterm birth (MACS): a randomised controlled trial. Lancet. 2008;372: 2143-2151.
410. Khan AA, Rodriguez A, Kaakinen M, Pouta A, Hartikainen AL, Jarvelin MR. Does in utero exposure to synthetic glucocorticoids influence birthweight, head circumference and birth length? A systematic review of current evidence in humans. Paediatr Perinat Epidemiol. 2011;25: 20-36.
411. Crowley PA. Antenatal corticosteroid therapy: a metaanalysis of the randomized trials, 1972 to 1994. Am J Obstet Gynecol. 1995;173:322-335.
412. Braun T, Li S, Moss TJ, et al. Differential appearance of placentomes and expression of prostaglandin H synthase type 2 in placentome subtypes after betamethasone treatment of sheep late in gestation. Placenta. 2011;32:295- 303.
413. Braun T, Husar A, Challis JR, et al. Growth restricting effects of a single course of antenatal betamethasone treatment and the role of human placental lactogen. 2013;34: 407-415.
414. Li S, Nitsos I, Polglase GR, et al. The effects of dexamethasone treatment in early gestation on hypothalamic-pituitary-adrenal responses and gene expression at 7 months of postnatal age in sheep. Reprod Sci. 2012;19:260-270.
415. Mastorakos G, Ilias I. Maternal and fetal hypothalamicpituitary-adrenal axes during pregnancy and postpartum. Ann N Y Acad Sci. 2003;997:136-149.
416. Grunau RE, Holsti L, Haley DW, et al. Neonatal procedural pain exposure predicts lower cortisol and behavioral reactivity in preterm infants in the NICU. Pain. 2005;113: 293-300.
417. Lunghi L, Pavan B, Biondi C, et al. Use of glucocorticoids in pregnancy. Curr Pharm Des. 2010;16:3616-3637.
418. Benediktsson R, Lindsay RS, Noble J, Seckl JR, Edwards CR. Glucocorticoid exposure in utero:newmodel for adult hypertension. Lancet. 1993;341:339-341.
419. Doyle LW, Ford GW, Rickards AL, et al. A Antenatal corticosteroids and outcome at 14 years of age in children with birth weight less than 1501 grams. Pediatrics. 2000;106: E2.